GNTI-122
Recently Diagnosed Type 1 Diabetes
Phase 1Active
Key Facts
About GentiBio
GentiBio is pioneering the development of engineered Treg (EngTreg) therapies, aiming to provide curative treatments for autoimmune and inflammatory diseases like Type 1 diabetes. The company has built a dual-platform strategy encompassing both autologous and proprietary 'off-the-shelf' allogeneic Tregs, engineered for specificity, stability, and immune evasion. Having advanced its lead candidate into Phase 1 clinical trials and secured key regulatory designations, GentiBio is positioned as a leader in translating Treg biology into scalable, transformative cell therapies. Its approach seeks to replace broad immunosuppression with targeted, tissue-restricted immune resetting and healing.
View full company profile